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Background
A number of investigative strategies exist for the diagno-
sis of coronary heart disease (CHD). Despite the wide-
spread availability of non-invasive imaging, invasive
angiography is commonly used early in the diagnostic
pathway. Consequently, approximately 60% of angio-
grams reveal no evidence of obstructive coronary dis-
ease. Reducing unnecessary angiography has potential
financial savings and avoids exposing the patient to
unnecessary risk. There are no large scale comparative
effectiveness trials of the different diagnostic strategies
recommended in international guidelines and none that
have evaluated the safety and efficacy of cardiovascular
magnetic resonance (CMR).
Methods
CE-MARC 2 is a prospective, multi-centre, 3-arm parallel
group, randomized controlled trial of patients with sus-
pected CHD (pre-test likelihood 10-90%) requiring further
investigation. 1200 patients will be randomized on a 2:2:1
basis to receive 3.0 Tesla CMR-guided care, single photon
emission computed tomography (SPECT) guided care
(according to ACC/AHA appropriate-use criteria) or
National Institute for Health and Care Excellence
guidelines-based management. The primary (efficacy) end-
point is the occurrence of unnecessary angiography as
defined by a normal (>0.8) invasive fractional flow reserve.
Safety of each strategy will be assessed by 3-year major
adverse cardiovascular event rates. Cost effectiveness and
health related quality of life (HRQoL) measures will be
performed.
Results
The CE-MARC 2 trial will provide comparative efficacy
and safety evidence for three different strategies of
investigating patient with suspected CHD, with the
intension of reducing unnecessary invasive angiography
rates.
Conclusions
Evaluation of these management strategies has the
potential to improve patient care, HRQoL and the cost
effectiveness of CHD investigation.
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Figure 1 CE-MARC 2 study flow diagram illustrating randomization, investigative strategy and study end-points.
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